Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00613769
Other study ID # TSM
Secondary ID EudraCT number 2
Status Completed
Phase Phase 4
First received January 31, 2008
Last updated September 27, 2012
Start date September 2007
Est. completion date May 2012

Study information

Verified date September 2012
Source Halmstad County Hospital
Contact n/a
Is FDA regulated No
Health authority Sweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

The current standard Swedish infection prophylaxis in colorectal surgery is intravenously administered cefuroxime and metronidazole. this combination is well studied. The disadvantages of the regimen is "collateral damage" resulting from treatment with a cephalosporine and that the combination also serves as the first line of treatment for abdominal surgical infections.

Serval Swedish surgical departments have for some years used a combination of orally administered trimethoprim-sulfamethoxazole and metronidazole.

The combination is economical and believed to be effective but hitherto the outcome have not been properly researched.

The aim of this study is to compare the efficacy of these two regimens in the prevention of infection after elective colorectal surgery.


Recruitment information / eligibility

Status Completed
Enrollment 1073
Est. completion date May 2012
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >= 18 years

- Planned clean/clean-contaminated colorectal resection will be performed

- Understand spoken and written swedish language

Exclusion Criteria:

- Hypersensibility to the test or control drug

- Severe liver failure

- Blood dyscrasia

- Ileus or gastric retention

- Current visceral perforation

- Current treatment with antibiotics

- Current treatment with steroids

- Cytotoxic or radiation therapy within 4 weeks of the planned operation

- Active IBD (inflammatory bowel disease)

- Incapability to swallow tablets

- Other study interfering with this study

- Current pregnancy

- Bad regulated diabetes

- Current enterocutaneous or colocutaneous fistula

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
trimethoprim-sulfamethoxazole + metronidazole
trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
cefuroxime and metronidazole
cefuromime 1500mg i.v. + metronidazole 1500mg i.v.

Locations

Country Name City State
Sweden Department of Surgery, University hospital Sahlgrenska/Östra Gothenburg
Sweden Department of Surgery and oncology, Halland Hospital in Halmstad Halmstad
Sweden Department of surgery, Community Hospital i Karlskrona Karlskrona
Sweden Vrinnevi hospital Norrköping
Sweden Department of surgery Skövde
Sweden Department of Surgery, NU-hospitals Uddevalla

Sponsors (1)

Lead Sponsor Collaborator
Halmstad County Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cutaneous-,subcutaneous and intraabdominal infections 4 weeks No
Secondary Non infectious wound complications 4 weeks No
Secondary Complications to the anastomosis 4 weeks No
Secondary Adverse reaction of given drug 4 weeks Yes
Secondary Other post operative infections During hospital stay No
Secondary Septicaemia 4 weeks No